Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 372

1.

Enhanced Depolarization Drive in Failing Rabbit Ventricular Myocytes.

Hegyi B, Morotti S, Liu C, Ginsburg KS, Bossuyt J, Belardinelli L, Izu LT, Chen-Izu Y, Bányász T, Grandi E, Bers DM.

Circ Arrhythm Electrophysiol. 2019 Mar;12(3):e007061. doi: 10.1161/CIRCEP.118.007061.

PMID:
30879336
2.

Atrial Fibrillation Initiated by Early Afterdepolarization-Mediated Triggered Activity during Acute Oxidative Stress: Efficacy of Late Sodium Current Blockade.

Pezhouman A, Cao H, Fishbein MC, Belardinelli L, Weiss JN, Karagueuzian HS.

J Heart Health. 2018 Apr 25;4(1). doi: 10.16966/2379-769X.146.

3.

Effect of autonomic influences to induce triggered activity in muscular sleeves extending into the coronary sinus of the canine heart and its suppression by ranolazine.

Sicouri S, Belardinelli L, Antzelevitch C.

J Cardiovasc Electrophysiol. 2019 Feb;30(2):230-238. doi: 10.1111/jce.13770. Epub 2018 Nov 2.

PMID:
30302862
4.

β-adrenergic regulation of late Na+ current during cardiac action potential is mediated by both PKA and CaMKII.

Hegyi B, Bányász T, Izu LT, Belardinelli L, Bers DM, Chen-Izu Y.

J Mol Cell Cardiol. 2018 Oct;123:168-179. doi: 10.1016/j.yjmcc.2018.09.006. Epub 2018 Sep 18.

PMID:
30240676
5.

Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, low-dose intratracheal or intravenous administration.

Marum AA, Silva BA, Bortolotto AL, Silva AC, de Antonio VZ, Belardinelli L, Verrier RL.

Int J Cardiol. 2019 Jan 1;274:170-174. doi: 10.1016/j.ijcard.2018.09.029. Epub 2018 Sep 8.

PMID:
30217428
6.

Pulmonary delivery of flecainide causes a rate-dependent predominant effect on atrial compared with ventricular depolarization duration revealed by intracardiac recordings in an intact porcine model.

de Antonio VZ, Silva AC, Stocco FG, Silva BA, Marum AA, Bortolotto AL, Belardinelli L, Verrier RL.

J Cardiovasc Electrophysiol. 2018 Nov;29(11):1563-1569. doi: 10.1111/jce.13708. Epub 2018 Sep 14.

PMID:
30106207
7.

Accelerated conversion of atrial fibrillation to normal sinus rhythm by pulmonary delivery of flecainide acetate in a porcine model.

Verrier RL, Bortolotto AL, Silva BA, Marum AA, Stocco FG, Evaristo E, de Antonio VZ, Silva AC, Belardinelli L.

Heart Rhythm. 2018 Dec;15(12):1882-1888. doi: 10.1016/j.hrthm.2018.06.036. Epub 2018 Jun 26.

PMID:
29958990
8.

Comparative Pharmacokinetic and Electrocardiographic Effects of Intratracheal and Intravenous Administration of Flecainide in Anesthetized Pigs.

Stocco FG, Evaristo E, Silva AC, de Antonio VZ, Pfeiffer J, Rangachari N, Belardinelli L, Verrier RL.

J Cardiovasc Pharmacol. 2018 Sep;72(3):129-135. doi: 10.1097/FJC.0000000000000605.

PMID:
29923887
9.

Enhanced late sodium current underlies pro-arrhythmic intracellular sodium and calcium dysregulation in murine sodium channelopathy.

Rivaud MR, Baartscheer A, Verkerk AO, Beekman L, Rajamani S, Belardinelli L, Bezzina CR, Remme CA.

Int J Cardiol. 2018 Jul 15;263:54-62. doi: 10.1016/j.ijcard.2018.03.044.

PMID:
29754923
10.

A common co-morbidity modulates disease expression and treatment efficacy in inherited cardiac sodium channelopathy.

Rivaud MR, Jansen JA, Postema PG, Nannenberg EA, Mizusawa Y, van der Nagel R, Wolswinkel R, van der Made I, Marchal GA, Rajamani S, Belardinelli L, van Tintelen JP, Tanck MWT, van der Wal AC, de Bakker JMT, van Rijen HV, Creemers EE, Wilde AAM, van den Berg MP, van Veen TAB, Bezzina CR, Remme CA.

Eur Heart J. 2018 Aug 14;39(31):2898-2907. doi: 10.1093/eurheartj/ehy247.

PMID:
29718149
11.

The novel CaMKII inhibitor GS-680 reduces diastolic SR Ca leak and prevents CaMKII-dependent pro-arrhythmic activity.

Lebek S, Plößl A, Baier M, Mustroph J, Tarnowski D, Lücht CM, Schopka S, Flörchinger B, Schmid C, Zausig Y, Pagratis N, Marchand B, Koltun DO, Hung WK, Ahmadyar S, Belardinelli L, Maier LS, Wagner S.

J Mol Cell Cardiol. 2018 May;118:159-168. doi: 10.1016/j.yjmcc.2018.03.020. Epub 2018 Mar 31.

PMID:
29614261
12.

Selective late sodium current inhibitor GS-458967 suppresses Torsades de Pointes by mostly affecting perpetuation but not initiation of the arrhythmia.

Bossu A, Houtman MJC, Meijborg VMF, Varkevisser R, Beekman HDM, Dunnink A, de Bakker JMT, Mollova N, Rajamani S, Belardinelli L, van der Heyden MAG, Vos MA.

Br J Pharmacol. 2018 Jun;175(12):2470-2482. doi: 10.1111/bph.14217. Epub 2018 May 6.

13.

Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium.

Ferrantini C, Pioner JM, Mazzoni L, Gentile F, Tosi B, Rossi A, Belardinelli L, Tesi C, Palandri C, Matucci R, Cerbai E, Olivotto I, Poggesi C, Mugelli A, Coppini R.

Br J Pharmacol. 2018 Jul;175(13):2635-2652. doi: 10.1111/bph.14223. Epub 2018 May 3.

14.

Complex electrophysiological remodeling in postinfarction ischemic heart failure.

Hegyi B, Bossuyt J, Griffiths LG, Shimkunas R, Coulibaly Z, Jian Z, Grimsrud KN, Sondergaard CS, Ginsburg KS, Chiamvimonvat N, Belardinelli L, Varró A, Papp JG, Pollesello P, Levijoki J, Izu LT, Boyd WD, Bányász T, Bers DM, Chen-Izu Y.

Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):E3036-E3044. doi: 10.1073/pnas.1718211115. Epub 2018 Mar 12.

15.

Enhanced basal late sodium current appears to underlie the age-related prolongation of action potential duration in guinea pig ventricular myocytes.

Song Y, Belardinelli L.

J Appl Physiol (1985). 2017 Dec 14. doi: 10.1152/japplphysiol.00916.2017. [Epub ahead of print]

PMID:
29357519
16.

Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study.

Olivotto I, Camici PG, Merlini PA, Rapezzi C, Patten M, Climent V, Sinagra G, Tomberli B, Marin F, Ehlermann P, Maier LS, Fornaro A, Jacobshagen C, Ganau A, Moretti L, Hernandez Madrid A, Coppini R, Reggiardo G, Poggesi C, Fattirolli F, Belardinelli L, Gensini G, Mugelli A.

Circ Heart Fail. 2018 Jan;11(1):e004124. doi: 10.1161/CIRCHEARTFAILURE.117.004124.

PMID:
29321131
17.

Pro-arrhythmic effects of low plasma [K+] in human ventricle: An illustrated review.

Trenor B, Cardona K, Romero L, Gomez JF, Saiz J, Rajamani S, Belardinelli L, Giles W.

Trends Cardiovasc Med. 2018 May;28(4):233-242. doi: 10.1016/j.tcm.2017.11.002. Epub 2017 Nov 24. Review.

PMID:
29203397
18.

Eleclazine exhibits enhanced selectivity for long QT syndrome type 3-associated late Na+ current.

El-Bizri N, Xie C, Liu L, Limberis J, Krause M, Hirakawa R, Nguyen S, Tabuena DR, Belardinelli L, Kahlig KM.

Heart Rhythm. 2018 Feb;15(2):277-286. doi: 10.1016/j.hrthm.2017.09.028. Epub 2017 Oct 7.

PMID:
29017927
19.

Selective inhibition of physiological late Na+ current stabilizes ventricular repolarization.

El-Bizri N, Li CH, Liu GX, Rajamani S, Belardinelli L.

Am J Physiol Heart Circ Physiol. 2018 Feb 1;314(2):H236-H245. doi: 10.1152/ajpheart.00071.2017. Epub 2017 Sep 29.

20.
21.

Modulation of late sodium current by Ca2+ -calmodulin-dependent protein kinase II, protein kinase C and Ca2+ during hypoxia in rabbit ventricular myocytes.

Fu C, Hao J, Zeng M, Song Y, Jiang W, Zhang P, Luo A, Cao Z, Belardinelli L, Ma J.

Exp Physiol. 2017 Jul 1;102(7):818-834. doi: 10.1113/EP085990.

22.

Anti-arrhythmic potential of the late sodium current inhibitor GS-458967 in murine Scn5a-1798insD+/- and human SCN5A-1795insD+/- iPSC-derived cardiomyocytes.

Portero V, Casini S, Hoekstra M, Verkerk AO, Mengarelli I, Belardinelli L, Rajamani S, Wilde AAM, Bezzina CR, Veldkamp MW, Remme CA.

Cardiovasc Res. 2017 Jun 1;113(7):829-838. doi: 10.1093/cvr/cvx077.

PMID:
28430892
23.

Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.

Coppini R, Mazzoni L, Ferrantini C, Gentile F, Pioner JM, Laurino A, Santini L, Bargelli V, Rotellini M, Bartolucci G, Crocini C, Sacconi L, Tesi C, Belardinelli L, Tardiff J, Mugelli A, Olivotto I, Cerbai E, Poggesi C.

Circ Heart Fail. 2017 Mar;10(3). pii: e003565. doi: 10.1161/CIRCHEARTFAILURE.116.003565.

24.

Ventricular Microanatomy, Arrhythmias, and the Electrochemical Driving Force for Na+: Is There a Need for Flipped Learning?

Belardinelli L, Maleckar MM, Giles WR.

Circ Arrhythm Electrophysiol. 2017 Feb;10(2):e004955. doi: 10.1161/CIRCEP.117.004955. No abstract available. Erratum in: Circ Arrhythm Electrophysiol. 2017 Mar;10 (3):.

PMID:
28213509
25.

The Selective Late Sodium Current Inhibitor Eleclazine, Unlike Amiodarone, Does Not Alter Defibrillation Threshold or Dominant Frequency of Ventricular Fibrillation.

Silva AF, Bonatti R, Batatinha JA, Nearing BD, Zeng D, Belardinelli L, Verrier RL.

J Cardiovasc Pharmacol. 2017 Mar;69(3):178-182. doi: 10.1097/FJC.0000000000000455.

PMID:
28045761
26.

Ranolazine for rhythm control in atrial fibrillation: A systematic review and meta-analysis.

Guerra F, Romandini A, Barbarossa A, Belardinelli L, Capucci A.

Int J Cardiol. 2017 Jan 15;227:284-291. doi: 10.1016/j.ijcard.2016.11.103. Epub 2016 Nov 9. Review.

PMID:
27839812
27.

Eleclazine, an inhibitor of the cardiac late sodium current, is superior to flecainide in suppressing catecholamine-induced ventricular tachycardia and T-wave alternans in an intact porcine model.

Bacic D, Carneiro JS, Bento AA, Nearing BD, Rajamani S, Belardinelli L, Verrier RL.

Heart Rhythm. 2017 Mar;14(3):448-454. doi: 10.1016/j.hrthm.2016.10.021. Epub 2016 Oct 21.

PMID:
27777148
28.

Inhibition of late sodium current attenuates ionic arrhythmia mechanism in ventricular myocytes expressing LaminA-N195K mutation.

Markandeya YS, Tsubouchi T, Hacker TA, Wolff MR, Belardinelli L, Balijepalli RC.

Heart Rhythm. 2016 Nov;13(11):2228-2236. doi: 10.1016/j.hrthm.2016.08.007. Epub 2016 Aug 3.

29.

Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.

Chorin E, Hu D, Antzelevitch C, Hochstadt A, Belardinelli L, Zeltser D, Barajas-Martinez H, Rozovski U, Rosso R, Adler A, Benhorin J, Viskin S.

Circ Arrhythm Electrophysiol. 2016 Oct;9(10). pii: e004370.

30.

Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late INai), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic Properties.

Zablocki JA, Elzein E, Li X, Koltun DO, Parkhill EQ, Kobayashi T, Martinez R, Corkey B, Jiang H, Perry T, Kalla R, Notte GT, Saunders O, Graupe M, Lu Y, Venkataramani C, Guerrero J, Perry J, Osier M, Strickley R, Liu G, Wang WQ, Hu L, Li XJ, El-Bizri N, Hirakawa R, Kahlig K, Xie C, Li CH, Dhalla AK, Rajamani S, Mollova N, Soohoo D, Lepist EI, Murray B, Rhodes G, Belardinelli L, Desai MC.

J Med Chem. 2016 Oct 13;59(19):9005-9017. doi: 10.1021/acs.jmedchem.6b00939. Epub 2016 Oct 3.

PMID:
27690427
31.

Early somatic mosaicism is a rare cause of long-QT syndrome.

Priest JR, Gawad C, Kahlig KM, Yu JK, O'Hara T, Boyle PM, Rajamani S, Clark MJ, Garcia ST, Ceresnak S, Harris J, Boyle S, Dewey FE, Malloy-Walton L, Dunn K, Grove M, Perez MV, Neff NF, Chen R, Maeda K, Dubin A, Belardinelli L, West J, Antolik C, Macaya D, Quertermous T, Trayanova NA, Quake SR, Ashley EA.

Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):11555-11560. Epub 2016 Sep 28.

32.

A computational model predicts adjunctive pharmacotherapy for cardiac safety via selective inhibition of the late cardiac Na current.

Yang PC, El-Bizri N, Romero L, Giles WR, Rajamani S, Belardinelli L, Clancy CE.

J Mol Cell Cardiol. 2016 Oct;99:151-161. doi: 10.1016/j.yjmcc.2016.08.011. Epub 2016 Aug 18.

33.

The novel late Na+ current inhibitor, GS-6615 (eleclazine) and its anti-arrhythmic effects in rabbit isolated heart preparations.

Rajamani S, Liu G, El-Bizri N, Guo D, Li C, Chen XL, Kahlig KM, Mollova N, Elzein E, Zablocki J, Belardinelli L.

Br J Pharmacol. 2016 Nov;173(21):3088-3098. doi: 10.1111/bph.13563. Epub 2016 Sep 14.

34.
35.

Eleclazine, a new selective cardiac late sodium current inhibitor, confers concurrent protection against autonomically induced atrial premature beats, repolarization alternans and heterogeneity, and atrial fibrillation in an intact porcine model.

Fuller H, Justo F, Nearing BD, Kahlig KM, Rajamani S, Belardinelli L, Verrier RL.

Heart Rhythm. 2016 Aug;13(8):1679-86. doi: 10.1016/j.hrthm.2016.04.015. Epub 2016 Apr 21.

PMID:
27108587
36.

Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine.

Koltun DO, Parkhill EQ, Elzein E, Kobayashi T, Notte GT, Kalla R, Jiang RH, Li X, Perry TD, Avila B, Wang WQ, Smith-Maxwell C, Dhalla AK, Rajamani S, Stafford B, Tang J, Mollova N, Belardinelli L, Zablocki JA.

Bioorg Med Chem Lett. 2016 Jul 1;26(13):3202-3206. doi: 10.1016/j.bmcl.2016.03.101. Epub 2016 Mar 30.

PMID:
27080178
37.

Inhibitions of late INa and CaMKII act synergistically to prevent ATX-II-induced atrial fibrillation in isolated rat right atria.

Liang F, Fan P, Jia J, Yang S, Jiang Z, Karpinski S, Kornyeyev D, Pagratis N, Belardinelli L, Yao L.

J Mol Cell Cardiol. 2016 May;94:122-130. doi: 10.1016/j.yjmcc.2016.04.001. Epub 2016 Apr 9.

PMID:
27066997
38.

The combined effects of ranolazine and dronedarone on human atrial and ventricular electrophysiology.

Hartmann N, Mason FE, Braun I, Pabel S, Voigt N, Schotola H, Fischer TH, Dobrev D, Danner BC, Renner A, Gummert J, Belardinelli L, Frey N, Maier LS, Hasenfuss G, Sossalla S.

J Mol Cell Cardiol. 2016 May;94:95-106. doi: 10.1016/j.yjmcc.2016.03.012. Epub 2016 Apr 4.

PMID:
27056421
39.

Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with improved efficacy and potency relative to ranolazine.

Koltun DO, Parkhill EQ, Elzein E, Kobayashi T, Jiang RH, Li X, Perry TD, Avila B, Wang WQ, Hirakawa R, Smith-Maxwell C, Wu L, Dhalla AK, Rajamani S, Mollova N, Stafford B, Tang J, Belardinelli L, Zablocki JA.

Bioorg Med Chem Lett. 2016 Jul 1;26(13):3207-3211. doi: 10.1016/j.bmcl.2016.03.096. Epub 2016 Mar 26.

PMID:
27038498
40.

Inhibition of late Na+ current, a novel target to improve diastolic function and electrical abnormalities in Dahl salt-sensitive rats.

Chi L, Belardinelli L, Zeng A, Hirakawa R, Rajamani S, Ling H, Dhalla AK.

Am J Physiol Heart Circ Physiol. 2016 May 15;310(10):H1313-20. doi: 10.1152/ajpheart.00863.2015. Epub 2016 Mar 18.

41.

Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial.

Olivotto I, Hellawell JL, Farzaneh-Far R, Blair C, Coppini R, Myers J, Belardinelli L, Maron MS.

Circ Heart Fail. 2016 Mar;9(3):e002764. doi: 10.1161/CIRCHEARTFAILURE.115.002764.

PMID:
26915375
42.

Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin.

Pettus J, McNabb B, Eckel RH, Skyler JS, Dhalla A, Guan S, Jochelson P, Belardinelli L, Henry RH.

Diabetes Obes Metab. 2016 May;18(5):463-74. doi: 10.1111/dom.12629. Epub 2016 Feb 23. Erratum in: Diabetes Obes Metab. 2018 Jul;20(7):1805.

PMID:
26749407
43.

Contribution of the late sodium current to intracellular sodium and calcium overload in rabbit ventricular myocytes treated by anemone toxin.

Kornyeyev D, El-Bizri N, Hirakawa R, Nguyen S, Viatchenko-Karpinski S, Yao L, Rajamani S, Belardinelli L.

Am J Physiol Heart Circ Physiol. 2016 Feb 1;310(3):H426-35. doi: 10.1152/ajpheart.00520.2015. Epub 2015 Dec 4.

44.

Unmasking atrial repolarization to assess alternans, spatiotemporal heterogeneity, and susceptibility to atrial fibrillation.

Verrier RL, Fuller H, Justo F, Nearing BD, Rajamani S, Belardinelli L.

Heart Rhythm. 2016 Apr;13(4):953-61. doi: 10.1016/j.hrthm.2015.11.019. Epub 2015 Nov 23.

PMID:
26592850
45.

Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial.

Arnold SV, McGuire DK, Spertus JA, Tang F, Yue P, Inzucchi SE, Belardinelli L, Chaitman BR, Kosiborod M.

Am Heart J. 2015 Oct;170(4):753-759.e2. doi: 10.1016/j.ahj.2015.07.025. Epub 2015 Jul 26.

PMID:
26386799
46.

The Selective Cardiac Late Sodium Current Inhibitor GS-458967 Suppresses Autonomically Triggered Atrial Fibrillation in an Intact Porcine Model.

Carneiro JS, Bento AS, Bacic D, Nearing BD, Rajamani S, Belardinelli L, Verrier RL.

J Cardiovasc Electrophysiol. 2015 Dec;26(12):1364-9. doi: 10.1111/jce.12824. Epub 2015 Oct 30.

PMID:
26331943
47.

The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.

Reiffel JA, Camm AJ, Belardinelli L, Zeng D, Karwatowska-Prokopczuk E, Olmsted A, Zareba W, Rosero S, Kowey P; HARMONY Investigators.

Circ Arrhythm Electrophysiol. 2015 Oct;8(5):1048-56. doi: 10.1161/CIRCEP.115.002856. Epub 2015 Jul 30.

PMID:
26226999
48.

Selective late INa inhibition by GS-458967 exerts parallel suppression of catecholamine-induced hemodynamically significant ventricular tachycardia and T-wave alternans in an intact porcine model.

Alves Bento AS, Bacic D, Saran Carneiro J, Nearing BD, Fuller H, Justo FA, Rajamani S, Belardinelli L, Verrier RL.

Heart Rhythm. 2015 Dec;12(12):2508-14. doi: 10.1016/j.hrthm.2015.07.025. Epub 2015 Jul 17.

PMID:
26190314
49.

Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial.

Gutierrez JA, Karwatowska-Prokopczuk E, Murphy SA, Belardinelli L, Farzaneh-Far R, Walker G, Morrow DA, Scirica BM.

Clin Cardiol. 2015 Aug;38(8):469-75. doi: 10.1002/clc.22425. Epub 2015 Jun 8.

50.

Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes.

Eckel RH, Henry RR, Yue P, Dhalla A, Wong P, Jochelson P, Belardinelli L, Skyler JS.

Diabetes Care. 2015 Jul;38(7):1189-96. doi: 10.2337/dc14-2629. Epub 2015 Jun 6.

Supplemental Content

Loading ...
Support Center